Cannabinoid Encyclopedia

Cannabinoid guide

What is CBDA?

A clear guide to CBDA: what it is, what researchers have studied, how strong the evidence is, and what to know about safety.

Updated July 2026 26 research sources Mostly early-stage research

The short answer

CBDA, in simple terms

CBDA is a cannabinoid-related compound represented in the scientific literature. Researchers study it for possible effects, safety, and how it works in the body. Most of the current evidence is preclinical or focused on biological mechanisms. The evidence does not turn this into one proven benefit, because studies can use different products, doses, routes, people, and outcomes. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBDA.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into CBDA

What CBDA is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Preclinical and mechanism-focused

    Nausea-related or inflammation-related outcomes

    Interest in CBDA and inflammation comes from studies of inflammatory or immune signals. A change in a laboratory or animal model is not proof of a human treatment effect. 2

    See research areas

  2. Mostly mechanism-focused

    Safety, adverse events, impairment, and formulation concerns

    Safety research asks how CBDA, its dose, route, formulation, and other medications may change risk. The available evidence may not answer the safety question for every product or person. 3

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    Research on CBDA covers Nausea-related or inflammation-related outcomes and Safety, adverse events, impairment, and formulation concerns; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What has CBDA been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Preclinical and mechanism-focused

Nausea-related or inflammation-related outcomes

Researchers have examined CBDA in connection with Nausea-related or inflammation-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 2

Mostly mechanism-focused

Safety, adverse events, impairment, and formulation concerns

Researchers have examined CBDA in connection with Safety, adverse events, impairment, and formulation concerns. The studies may differ in compound, formulation, dose, route, population, and outcome. 3

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

7 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

5 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

8 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 6 of 26 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBDA is not one kind of study. This source set includes 10 animal studies, 5 narrative or expert reviews, 2 cell or laboratory studies, and 2 clinical studies in people. 3

The recorded populations or models include animal models (8 sources), people or patients (7 sources), and cells or tissue models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is nausea-related or inflammation-related outcomes (25 sources) and safety, adverse-event, impairment, or formulation-specific concerns (1 source). Closely related outcome names can still describe different measurements. 5

The CBDA source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

(‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research.

On this page, this source examines CBDA and nausea-related or inflammation-related outcomes. 1

Study type
narrative or expert review
Outcome focus
nausea-related or inflammation-related outcomes
Evidence stage
evidence still limited

narrative or expert review

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

On this page, this source examines CBDA and nausea-related or inflammation-related outcomes. 2

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
nausea-related or inflammation-related outcomes
Evidence stage
evidence still limited

clinical study in people

Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs.

On this page, this source examines CBDA and safety, adverse-event, impairment, or formulation-specific concerns. 3

Study type
clinical study in people
Population or model
people or patients
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns
Evidence stage
mechanism-focused research

clinical study in people

A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.

On this page, this source examines CBDA and nausea-related or inflammation-related outcomes. 4

Study type
clinical study in people
Population or model
animal models
Outcome focus
nausea-related or inflammation-related outcomes
Evidence stage
mechanism-focused research

narrative or expert review

Effects of Cannabidiol on Locomotor Activity.

On this page, this source examines CBDA and nausea-related or inflammation-related outcomes. 5

Study type
narrative or expert review
Outcome focus
nausea-related or inflammation-related outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CBDA should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 3

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is CBDA?

CBDA is a cannabinoid-related compound studied across Nausea-related or inflammation-related outcomes and Safety, adverse events, impairment, and formulation concerns. This page separates those research questions so they are not mistaken for one broad claim. 7

What has CBDA been studied for?

The current source set includes Nausea-related or inflammation-related outcomes and Safety, adverse events, impairment, and formulation concerns. Each area may use different doses, products, routes, populations, and outcome measures. 8

How strong is the research on CBDA?

Most of the current evidence is preclinical or focused on biological mechanisms. 9

Is CBDA safe?

Safety cannot be answered for CBDA without context. Dose, route, formulation, medications, and the person using it can all change risk. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    (‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. narrative or expert review; evidence still limited PubMed 32517131 DOI 10.3390/molecules25112638
  2. 2
    Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. narrative or expert review; evidence still limited PubMed 30627539 DOI 10.1155/2018/1691428
  3. 3
    Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. clinical study in people; mechanism-focused research PubMed 41822224 DOI 10.3389/fvets.2026.1779760
  4. 4
    A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. clinical study in people; mechanism-focused research PubMed 24595502 DOI 10.1007/s00213-014-3498-1
  5. 5
    Effects of Cannabidiol on Locomotor Activity. narrative or expert review; evidence still limited PubMed 35629320 DOI 10.3390/life12050652
  6. 6
    Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited PubMed 41545891 DOI 10.1186/s42238-026-00387-y
  7. 7
    Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. narrative or expert review; evidence still limited PubMed 34115951 DOI 10.1089/can.2021.0041
  8. 8
    Behavioural and molecular effects of cannabidiolic acid in mice. animal study; mechanism-focused research PubMed 32798553 DOI 10.1016/j.lfs.2020.118271
  9. 9
    Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. animal study; mechanism-focused research PubMed 29057454 DOI 10.1111/bph.14073
  10. 10
    Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. animal study; mechanism-focused research PubMed 23121618 DOI 10.1111/bph.12043
  11. 11
    Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. animal study; mechanism-focused research PubMed 30225659 DOI 10.1007/s00213-018-5034-1
  12. 12
    Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping. animal study; preclinical research PubMed 26381155 DOI 10.1007/s00213-015-4080-1
See all 26 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. narrative or expert review; evidence still limited / 1 linked research note PubMed 30627539
  2. Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited / 1 linked research note PubMed 41545891
  3. Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. narrative or expert review; evidence still limited / 1 linked research note PubMed 34115951
  4. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. animal study; mechanism-focused research / 1 linked research note PubMed 29057454
  5. Evaluation of Sex Differences in the Potential of Δ9-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats. animal study; preclinical research / 1 linked research note PubMed 35984924
  6. Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. animal study; mechanism-focused research / 1 linked research note PubMed 32488349
  7. Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. animal study; mechanism-focused research / 1 linked research note PubMed 31897571
  8. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. animal study; mechanism-focused research / 1 linked research note PubMed 23121618
  9. Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. animal study; preclinical research / 1 linked research note PubMed 26439367
  10. A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. clinical study in people; mechanism-focused research / 1 linked research note PubMed 24595502
  11. Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping. animal study; preclinical research / 1 linked research note PubMed 26381155
  12. Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid. animal study; preclinical research / 1 linked research note PubMed 24012649
  13. Short term feeding of industrial hemp with a high cannabidiolic acid (CBDA) content increases lying behavior and reduces biomarkers of stress and inflammation in Holstein steers. evidence still limited / 1 linked research note PubMed 35256692
  14. Antiviral activities of hemp cannabinoids. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37083031
  15. Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. animal study; mechanism-focused research / 1 linked research note PubMed 30225659
  16. Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients. evidence still limited / 1 linked research note PubMed 36342776
  17. Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis. evidence still limited / 1 linked research note PubMed 32401504
  18. Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. evidence still limited / 1 linked research note PubMed 32735381
  19. Phytochemical Analysis of the Methanolic Extract and Essential Oil from Leaves of Industrial Hemp Futura 75 Cultivar: Isolation of a New Cannabinoid Derivative and Biological Profile Using Computational Approaches. evidence still limited / 1 linked research note PubMed 35807623
  20. The effect of phytocannabinoids on airway hyper-responsiveness, airway inflammation, and cough. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 25655949
  21. (‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. narrative or expert review; evidence still limited / 1 linked research note PubMed 32517131
  22. Effects of Cannabidiol on Locomotor Activity. narrative or expert review; evidence still limited / 1 linked research note PubMed 35629320
  23. Behavioural and molecular effects of cannabidiolic acid in mice. animal study; mechanism-focused research / 1 linked research note PubMed 32798553
  24. Synergy between cannabidiol, cannabidiolic acid, and Δ⁹-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). evidence still limited / 1 linked research note PubMed 26030435
  25. Alginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid. evidence still limited / 1 linked research note PubMed 39667593
  26. Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. clinical study in people; mechanism-focused research / 1 linked research note PubMed 41822224